Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01590615 · ClinicalTrials.gov registry record
Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy
A clinical trial, sponsored by Gilead Sciences.
- Completed
- Registry status
- 54
- Enrollment target
NCT01590615 is a clinical trial that has completed, run by Gilead Sciences. The registered enrollment target is 54 participants.
The verdict
NCT01590615 has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- 54 participants
- Enrollment target
Study Summary
This registry will remain open for approximately 5 years (4 years of enrollment + 1 year of follow up). Subjects will be followed until Orthotopic Liver Transplant (OLT), resolution of liver decompensation, death, or conclusion of the registry.
Interventions
- DRUG Anti-HBV nucleoside/nucleotide therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2012-04-26 |
| Est. Completion | 2017-04-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01590615
The ClinicalTrials.gov registry entry for NCT01590615 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anti-HBV nucleoside/nucleotide therapy is the first listed.
NCT01590615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01590615 about?
NCT01590615 is a clinical study titled "Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy". This registry will remain open for approximately 5 years (4 years of enrollment + 1 year of follow up). Subjects will be followed until Orthotopic Liver Transplant (OLT), resolution of liver decompensation, death, or conclusion of the registry.
What is the current status of trial NCT01590615?
This trial is currently completed. The enrollment target is 54 participants. The study started on 2012-04-26. Estimated completion is 2017-04-04.
What interventions are being tested in trial NCT01590615?
The interventions under investigation include: Anti-HBV nucleoside/nucleotide therapy (DRUG).
Who is sponsoring clinical trial NCT01590615?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.